All In Biotech

Drug Trial Radar · NCT02283177

A Safety and Tolerability Study of Crenolanib in Combination With Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients With FLT3 Mutations

A Safety and Tolerability Trial of Crenolanib and Chemotherapy With Cytarabine and Anthracyclines in Patients With Newly Diagnosed Acute Myeloid Leukemia With FLT3 Activating Mutations

Last checked: Nov 19, 2026Latest source record: Feb 2, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

44

Actual

Start

Jan 2015

Primary completion

Dec 2019

Study completion Dec 2019

Sponsor

Lead sponsor
Arog Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Nov 5, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This pilot study is designed to evaluate the safety and tolerability of oral crenolanib besylate given sequentially during standard induction and consolidation chemotherapy in patients with newly diagnosed AML with FLT3 activating mutations.

Conditions

  • Newly Diagnosed AML With FLT3 Activating Mutations

Interventions

  • crenolanibDrug

  • cytarabineDrug

  • daunorubicinDrug

  • idarubicinDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Clinical Response to Crenolanib With Standard Induction ChemotherapyTime frame: 2 years

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • City of Hope Medical Center

    Duarte, California

  • University of Iowa Hospitals and Clinics

    Iowa City, Iowa

  • Dana-Farber Cancer Institute

    Boston, Massachusetts

  • Roswell Park Cancer Institute

    Buffalo, New York

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • Weill Cornell Medical College

    New York, New York

  • Cleveland Clinic

    Cleveland, Ohio

  • University of Texas Southwestern Medical Center

    Dallas, Texas

  • Fred Hutchinson Cancer Research Center

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.